Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR to Present at Upcoming Investor Conferences

GlobeNewswire November 13, 2019

ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

GlobeNewswire November 6, 2019

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire October 18, 2019

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

GlobeNewswire October 15, 2019

ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

GlobeNewswire October 15, 2019

ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

Thomson Reuters ONE October 10, 2019

ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

GlobeNewswire October 10, 2019

ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

GlobeNewswire October 7, 2019

ProQR to Present at Two Investor Conferences in October

GlobeNewswire September 30, 2019

ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

GlobeNewswire September 9, 2019

ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

GlobeNewswire August 12, 2019

ProQR Announces Financial Results for the Second Quarter of 2019

GlobeNewswire August 7, 2019

European Medicines Agency Grants PRIME Access to ProQR's Sepofarsen for Leber's Congenital Amaurosis 10

GlobeNewswire July 29, 2019

European Medicines Agency Grants PRIME Access to ProQR's Sepofarsen for Leber's Congenital Amaurosis 10

Thomson Reuters ONE July 29, 2019

ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July

GlobeNewswire July 2, 2019

ProQR to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 3, 2019

ProQR to Present at the RBC Capital Markets Healthcare Conference

GlobeNewswire May 15, 2019

ProQR Announces Financial Results for the First Quarter of 2019

GlobeNewswire May 8, 2019

ProQR to Present at Three Scientific Conferences in April

GlobeNewswire April 22, 2019

ProQR Announces Annual Meeting of Shareholders

GlobeNewswire April 18, 2019